Publications by authors named "P Linsley"

Article Synopsis
  • - Teplizumab is an approved treatment for delaying type 1 diabetes (T1D) in patients at risk, with recent studies revealing that 36% of participants were either undiagnosed or remained diabetes-free after 5 years, indicating potential operational tolerance.
  • - Analysis of CD8+ T cells showed initial activation signs post-treatment, which reverted after 18 months, with reduced gene expression linked to T cell response in those who responded positively to the drug while showing increased exhaustion markers.
  • - The study concluded that teplizumab helps promote operational tolerance in T1D by inducing T cell exhaustion and preventing the growth of autoantigen-reactive T cells over time.
View Article and Find Full Text PDF

Distinct Natural Killer (NK)-like CD57 and PD-1 CD8 exhausted-like T cell populations (Tex) have both been linked to beneficial immunotherapy response in autoimmune type 1 diabetes (T1D) patients. The origins and relationships between these cell types are poorly understood. Here we show that while PD-1 and CD57 Tex populations are epigenetically similar, CD57 Tex cells display unique increased chromatin accessibility of inhibitory Killer Cell Immunoglobulin-like Receptor (iKIR) and other NK cell genes.

View Article and Find Full Text PDF

Human type 1 diabetes (T1D) is caused by autoimmune attack on the insulin-producing pancreatic beta cells by islet antigen-reactive T cells. How human islet antigen-reactive (IAR) CD4+ memory T cells from peripheral blood affect T1D progression in the pancreas is poorly understood. Here, we aim to determine if IAR T cells in blood could be detected in pancreas.

View Article and Find Full Text PDF

Biomarkers are critical to the staging and diagnosis of type 1 diabetes (T1D). Functional biomarkers offer insights into T1D immunopathogenesis and are often revealed using "omics" approaches that integrate multiple measures to identify involved pathways and functions. Application of the omics biomarker discovery may enable personalized medicine approaches to circumvent the more recently appreciated heterogeneity of T1D progression and treatment.

View Article and Find Full Text PDF

Exhausted CD8 T cells (T) are associated with worse outcome in cancer yet better outcome in autoimmunity. Building on our past findings of increased TIGITKLRG1 T with teplizumab therapy in type 1 diabetes (T1D), in the absence of treatment we found that the frequency of TIGITKLRG1 T is stable within an individual but differs across individuals in both T1D and healthy control (HC) cohorts. This TIGITKLRG1 CD8 T population shares an exhaustion-associated EOMES gene signature in HC, T1D, rheumatoid arthritis (RA), and cancer subjects, expresses multiple inhibitory receptors, and is hyporesponsive , together suggesting co-expression of TIGIT and KLRG1 may broadly define human peripheral exhausted cells.

View Article and Find Full Text PDF